Drug Trial Radar · NCT04422912
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 29, 2020
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- Cabaletta BioIndustry
- Sponsor type
- Industry
- First posted
- Jun 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris
Conditions
- Pemphigus Vulgaris
Interventions
DSG3-CAARTBiological
Intravenous infusions of DSG3-CAART alone at different doses and different fractionations, with or without intravenous immunoglobulin, cyclophosphamide, and/or fludarabine.
CABA-201Biological
Single intravenous infusion of CABA-201 at escalating doses, with or without preconditioning.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events, including Dose Limit ToxicityTime frame: 3 months
- For CABA-201 Sub-study: To evaluate adverse events reported by subjectsTime frame: Up to 28 days after CABA-201 infusion
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Stanford University, Dept. of Dermatology
Redwood City, California · Recruiting
UC Davis, Dept. of Dermatology
Sacramento, California · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Mount Sinai - Icahn School of Medicine
New York, New York · Withdrawn
Columbia University
New York, New York · Recruiting
University of North Carolina, Department of Dermatology
Chapel Hill, North Carolina · Withdrawn
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
UT Southwestern Medical Center, Dept. of Dermatology
Dallas, Texas · Recruiting
MD Anderson Texas Medical Center
Houston, Texas · Recruiting
University of Washington
Seattle, Washington · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.